Dysregulation of vitamin D3 synthesis leads to enhanced cholangiocarcinoma growth

Digestive and Liver Disease

Volumn 45, Issue 4, 2013, Pages 316-322

  Kennedy, Lindsey ^a   Baker, Kimberly ^a   Hodges, Kyle ^a   Graf, Allyson ^a   Venter, Julie ^a   Hargrove, Laura ^a   Harris, Rachel ^a   Harnish, Evan ^a   Meng, Fanyin ^a   Francis, Heather ^a  

^a TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

Author keywords

Cholangiocarcinoma; Degradation; Growth; Synthesis; Vitamin D3

Indexed keywords

COLECALCIFEROL; COLECALCIFEROL RECEPTOR; CYTOCHROME P450; CYTOCHROME P450 24A1; CYTOCHROME P450 27B1; UNCLASSIFIED DRUG; CALCIDIOL 1 MONOOXYGENASE; CALCITRIOL RECEPTOR; MESSENGER RNA; STEROID MONOOXYGENASE; VITAMIN; VITAMIN D 24 HYDROXYLASE; VITAMIN D 24-HYDROXYLASE;

ARTICLE; BILE DUCT CARCINOMA; BIOSYNTHESIS; CANCER CELL; CANCER GROWTH; CELL TYPE; CELL VIABILITY; CHOLANGIOCYTE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR BIOPSY; BILE DUCT TUMOR; CELL PROLIFERATION; DRUG EFFECT; GENETICS; INTRAHEPATIC BILE DUCT; METABOLISM; PROTEIN TRANSPORT; TUMOR CELL LINE;

25-HYDROXYVITAMIN D3 1-ALPHA-HYDROXYLASE; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CELL LINE, TUMOR; CELL PROLIFERATION; CHOLANGIOCARCINOMA; CHOLECALCIFEROL; HUMANS; PROTEIN TRANSPORT; RECEPTORS, CALCITRIOL; RNA, MESSENGER; STEROID HYDROXYLASES; VITAMINS;

EID: 84875232774     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2012.12.012     Document Type: Article

References (48)

1. Sirica A.E. Cholangiocarcinoma: molecular targeting strategies for chemoprevention and therapy. Hepatology 2005, 41:5-15.
2. 4 histamine receptor agonist, clobenpropit, suppresses human cholangiocarcinoma progression by disruption of epithelial mesenchymal transition and tumor metastasis. Hepatology 2011, 54:1718-1728.
3. Onori P., Gaudio E., Franchitto A., et al. Histamine regulation of hyperplastic and neoplastic cell growth in cholangiocytes. World Journal of Gastrointestinal Pathophysiology 2010, 1:38-49.
4. 3 histamine receptor-mediated activation of protein kinase Calpha inhibits the growth of cholangiocarcinoma in vitro and in vivo. Molecular Cancer Research 2009, 7:1704-1713.
5. Ustundag Y., Bayraktar Y. Cholangiocarcinoma: a compact review of the literature. World Journal of Gastroenterology 2008, 14:6458-6466.
6. Henson D.E., Albores-Saavedra J., Corle D. Carcinoma of the extrahepatic bile ducts. Histologic types, stage of disease, grade, and survival rates. Cancer 1992, 70:1498-1501.
7. Han Y., Demorrow S., Invernizzi P., et al. Melatonin exerts by an autocrine loop antiproliferative effects in cholangiocarcinoma: its synthesis is reduced favoring cholangiocarcinoma growth. American Journal of Physiology. Gastrointestinal and Liver Physiology 2011, 301:G623-G633.
8. White J.H. Vitamin D metabolism and signaling in the immune system. Reviews in Endocrine and Metabolic Disorders 2012, 13:21-29.
9. Tissandie E., Gueguen Y., Lobaccaro J.M., et al. Vitamin D: metabolism, regulation and associated diseases. Medical Sciences (Paris) 2006, 22:1095-1100.
10. Seubwai W., Wongkham C., Puapairoj A., et al. Overexpression of vitamin D receptor indicates a good prognosis for cholangiocarcinoma: implications for therapeutics. Cancer 2007, 109:2497-2505.
11. 3. Bioscience, Biotechnology, and Biochemistry 2011, 75:208-213.
12. Issa L.L., Leong G.M., Eisman J.A. Molecular mechanism of vitamin D receptor action. Inflammation Research 1998, 47:451-475.
13. Kostner K., Denzer N., Muller C.S., et al. The relevance of vitamin D receptor (VDR) gene polymorphisms for cancer: a review of the literature. Anticancer Research 2009, 29:3511-3536.
14. Lehmann B., Querings K., Reichrath J. Vitamin D and skin: new aspects for dermatology. Experimental Dermatology 2004, 13:11-15.
15. Tangpricha V., Flanagan J.N., Whitlatch L.W., et al. 25-Hydroxyvitamin D-1alpha-hydroxylase in normal and malignant colon tissue. Lancet 2001, 357:1673-1674.
16. Zehnder D., Bland R., Williams M.C., et al. Extrarenal expression of 25-hydroxyvitamin d(3)-1 alpha-hydroxylase. Journal of Clinical Endocrinology and Metabolism 2001, 86:888-894.
17. 3-1alpha-hydroxylase in human health and disease. Journal of Steroid Biochemistry and Molecular Biology 2007, 103:316-321.
18. Francis H., DeMorrow S., Venter J., et al. Inhibition of histidine decarboxylase ablates the autocrine tumorigenic effects of histamine in human cholangiocarcinoma. Gut 2012, 61:753-764.
19. Knuth A., Gabbert H., Dippold W., et al. Biliary adenocarcinoma. Characterisation of three new human tumor cell lines. Journal of Hepatology 1985, 1:579-596.
20. Holzinger F., Z'Graggen K., Buchler M.W. Mechanisms of biliary carcinogenesis: a pathogenetic multi-stage cascade towards cholangiocarcinoma. Annals of Oncology 1999, 10:122-126.
21. Klatskin G. Adenocarcinoma of the hepatic duct at its bifurcation within the porta hepatis. An unusual tumor with distinctive clinical and pathological features. American Journal of Medicine 1965, 38:241-256.
22. Kusaka Y., Muraoka A., Tokiwa T., et al. Establishment and characterization of a human cholangiocellular carcinoma cell line. Human Cell 1988, 1:92-94.
23. Grubman S.A., Perrone R.D., Lee D.W., et al. Regulation of intracellular pH by immortalized human intrahepatic biliary epithelial cell lines. American Journal of Physiology-Gastrointestinal and Liver Physiology 1994, 266:G1060-G1070.
24. 2+-dependent protein kinase C-alpha. Journal of Hepatology 2001, 284-291.
25. 3/CaMK I/CREB pathway. American Journal of Physiology Cell Physiology 2008, 295:C499-C513.
26. 2+ and cAMP-dependent signaling mechanisms. Laboratory Investigation 2012, 92:282-294.
27. Coufal M., Invernizzi P., Gaudio E., et al. Increased local dopamine secretion has growth-promoting effects in cholangiocarcinoma. International Journal of Cancer 2010, 126:2112-2122.
28. 3 histamine receptor agonist inhibits biliary growth of BDL rats by downregulation of the cAMP-dependent PKA/ERK1/2/ELK-1 pathway. Laboratory Investigation 2007, 87:473-487.
29. Francis H., Glaser S., Ueno Y., et al. cAMP stimulates the secretory and proliferative capacity of the rat intrahepatic biliary epithelium through changes in the PKA/Src/MEK/ERK1/2 pathway. Journal of Hepatology 2004, 41:528-537.
30. Marzioni M., Glaser S., Francis H., et al. Autocrine/paracrine regulation of the growth of the biliary tree by the neuroendocrine hormone serotonin. Gastroenterology 2005, 128:121-137.
31. Deeb K.K., Trump D.L., Johnson C.S. Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nature Reviews Cancer 2007, 7:684-700.
32. Ramnath N., Kim S., Christensen P.J. Vitamin D and lung cancer. Expert Review of Respiratory and Medicine 2011, 5:305-309.
33. Hershberger P.A., Modzelewski R.A., Shurin Z.R., et al. 1,25-Dihydroxycholecalciferol (1,25-D3) inhibits the growth of squamous cell carcinoma and down-modulates p21(Waf1/Cip1) in vitro and in vivo. Cancer Research 1999, 59:2644-2649.
34. McGuire T.F., Trump D.L., Johnson C.S. Vitamin D(3)-induced apoptosis of murine squamous cell carcinoma cells. Selective induction of caspase-dependent MEK cleavage and up-regulation of MEKK-1. Journal of Biological Chemistry 2001, 276:26365-26373.
35. Bernardi R.J., Trump D.L., Yu W.D., et al. Combination of 1alpha,25-dihydroxyvitamin D(3) with dexamethasone enhances cell cycle arrest and apoptosis: role of nuclear receptor cross-talk and Erk/Akt signaling. Clinical Cancer Research 2001, 7:4164-4173.
36. Welsh J. Vitamin D metabolism in mammary gland and breast cancer. Molecular and Cellular Endocrinology 2011, 347:55-60.
37. Chen G., Kim S.H., King A.N., et al. CYP24A1 is an independent prognostic marker of survival in patients with lung adenocarcinoma. Clinical Cancer Research 2011, 17:817-826.
38. Zhang Q., Kanterewicz B., Buch S., et al. CYP24 inhibition preserves 1alpha,25-dihydroxyvitamin D(3) anti-proliferative signaling in lung cancer cells. Molecular and Cellular Endocrinology 2012, 355:153-161.
39. Hansdottir S., Monick M.M., Hinde S.L., et al. Respiratory epithelial cells convert inactive vitamin D to its active form: potential effects on host defense. Journal of Immunology 2008, 181:7090-7099.
40. McElwain M.C., Modzelewski R.A., Yu W.D., et al. Vitamin D: an antiproliferative agent with potential for therapy of squamous cell carcinoma. American Journal of Otolaryngology 1997, 18:293-298.
41. 3 inhibits metastasis and angiogenesis in lung cancer. Carcinogenesis 2005, 26:1044-1054.
42. Alpini G., Invernizzi P., Gaudio E., et al. Serotonin metabolism is dysregulated in cholangiocarcinoma, which has implications for tumor growth. Cancer Research 2008, 68:9184-9193.
43. 3. Cancer Letters 2000, 151:97-102.
44. Chiang K.C., Yeh C.N., Chen M.F., et al. Hepatocellular carcinoma and vitamin D: a review. Journal of Gastroenterology and Hepatology 2011, 26:1597-1603.
45. 3 induces elevated expression of the cell cycle-regulating genes P21 and P27 in squamous carcinoma cell lines of the head and neck. Acta Otolaryngology 2001, 121:103-109.
46. 3 and its analogue, EB1089, in human breast cancer cells. Oncogene 1997, 15:1555-1563.
47. 3 analog, EB 1089, with ionizing radiation reduces tumor growth and induces apoptosis of MCF-7 breast tumor xenografts in nude mice. Clinical Cancer Research 2003, 9:2350-2356.
48. Li Q., Gao Y., Jia Z., et al. Dysregulated Kruppel-like factor 4 and Vitamin D receptor signaling promotes hepatocellular carcinoma progression. Gastroenterology 2012, 143:799-810. e1-2. 10.1053/j.gastro.2012.05.043.